BR0316364A - Combinação de terapia do câncer com um composto anticâncer ativado com gst e uma outra terapia anticâncer - Google Patents
Combinação de terapia do câncer com um composto anticâncer ativado com gst e uma outra terapia anticâncerInfo
- Publication number
- BR0316364A BR0316364A BR0316364-4A BR0316364A BR0316364A BR 0316364 A BR0316364 A BR 0316364A BR 0316364 A BR0316364 A BR 0316364A BR 0316364 A BR0316364 A BR 0316364A
- Authority
- BR
- Brazil
- Prior art keywords
- gst
- therapy
- anticancer
- compound
- activated
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 8
- 230000001093 anti-cancer Effects 0.000 title abstract 7
- 238000011319 anticancer therapy Methods 0.000 title abstract 5
- 238000011275 oncology therapy Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 abstract 5
- 241000124008 Mammalia Species 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- NECZZOFFLFZNHL-XVGZVFJZSA-N (2s)-2-amino-5-[[(2r)-3-[2-[bis[bis(2-chloroethyl)amino]-oxidophosphaniumyl]oxyethylsulfonyl]-1-[[(r)-carboxy(phenyl)methyl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)P(=O)(N(CCCl)CCCl)OCCS(=O)(=O)C[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)N[C@@H](C(O)=O)C1=CC=CC=C1 NECZZOFFLFZNHL-XVGZVFJZSA-N 0.000 abstract 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 abstract 1
- 108700011582 TER 286 Proteins 0.000 abstract 1
- 229950000772 canfosfamide Drugs 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42698302P | 2002-11-15 | 2002-11-15 | |
| PCT/US2003/036209 WO2004045593A2 (en) | 2002-11-15 | 2003-11-14 | Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0316364A true BR0316364A (pt) | 2005-10-04 |
Family
ID=32326463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0316364-4A BR0316364A (pt) | 2002-11-15 | 2003-11-14 | Combinação de terapia do câncer com um composto anticâncer ativado com gst e uma outra terapia anticâncer |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20040138140A1 (enExample) |
| EP (1) | EP1562564A2 (enExample) |
| JP (2) | JP2006508980A (enExample) |
| KR (1) | KR20050075018A (enExample) |
| CN (2) | CN101590229B (enExample) |
| AR (1) | AR042051A1 (enExample) |
| AU (2) | AU2003290805A1 (enExample) |
| BR (1) | BR0316364A (enExample) |
| CA (1) | CA2505377A1 (enExample) |
| MX (1) | MXPA05005200A (enExample) |
| TW (1) | TWI323662B (enExample) |
| WO (1) | WO2004045593A2 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0011903D0 (en) * | 2000-05-18 | 2000-07-05 | Astrazeneca Ab | Combination chemotherapy |
| TW200538149A (en) | 2004-05-20 | 2005-12-01 | Telik Inc | Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound |
| JP5371426B2 (ja) * | 2004-07-09 | 2013-12-18 | プロルックス ファーマシューティカルズ コープ． | ワートマニン類似体及び化学療法薬と組み合わせた同一物を使用する方法 |
| WO2006074249A1 (en) * | 2005-01-06 | 2006-07-13 | Telik, Inc. | Tripeptide and tetrapeptide thioethers |
| US8168661B2 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8173686B2 (en) | 2006-11-06 | 2012-05-08 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8168662B1 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8178564B2 (en) * | 2006-11-06 | 2012-05-15 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US20110033528A1 (en) * | 2009-08-05 | 2011-02-10 | Poniard Pharmaceuticals, Inc. | Stabilized picoplatin oral dosage form |
| US20100260832A1 (en) * | 2007-06-27 | 2010-10-14 | Poniard Pharmaceuticals, Inc. | Combination therapy for ovarian cancer |
| TW200916094A (en) * | 2007-06-27 | 2009-04-16 | Poniard Pharmaceuticals Inc | Stabilized picoplatin dosage form |
| TW200920347A (en) * | 2007-07-16 | 2009-05-16 | Poniard Pharmaceuticals Inc | Oral formulations for picoplatin |
| HRP20160949T1 (hr) * | 2007-09-10 | 2016-10-07 | Boston Biomedical, Inc. | Novi sastavi i metode za liječenje karcinoma |
| JP2011511072A (ja) * | 2008-02-08 | 2011-04-07 | ポニアード ファーマシューティカルズ， インコーポレイテッド | 結腸直腸癌を治療するためのピコプラチンおよびベバシツマブの使用 |
| AU2009228303B2 (en) * | 2008-03-25 | 2015-08-13 | Paloma Pharmaceuticals, Inc. | Methods of treating fibrotic disorders |
| WO2010086964A1 (ja) * | 2009-01-28 | 2010-08-05 | 株式会社 静岡カフェイン工業所 | がん治療のための併用療法 |
| EP2425830A1 (en) * | 2010-09-03 | 2012-03-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Synergistic drug combination for the treatment of cancer |
| US20140296178A1 (en) * | 2010-12-01 | 2014-10-02 | Niiki Pharma Acquisition Corp. 2 | Combination Therapy with a Gallium Complex |
| WO2012112791A1 (en) * | 2011-02-16 | 2012-08-23 | Paloma Pharmaceuticals, Inc. | Radiation countermeasure agents |
| US20120251496A1 (en) * | 2011-03-31 | 2012-10-04 | Telik, Inc. | Ezatiostat for treating multiple myeloma |
| WO2014169078A2 (en) | 2013-04-09 | 2014-10-16 | Boston Biomedical, Inc. | Methods for treating cancer |
| US20170080093A1 (en) * | 2013-10-22 | 2017-03-23 | Tyme, Inc. | Tyrosine Derivatives And Compositions Comprising Them |
| BR112017000800A8 (pt) * | 2014-07-17 | 2023-04-25 | Biocurity Holdings Inc | Tratamento do câncer com uma combinação de radiação, nanoparticulas de óxido de cério, e um agente quimioterápico |
| US11389536B2 (en) | 2015-07-17 | 2022-07-19 | BioCurity Pharmaceuticals Inc. | Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent |
| CA3045306A1 (en) | 2016-11-29 | 2018-06-07 | Boston Biomedical, Inc. | Naphthofuran derivatives, preparation, and methods of use thereof |
| EA201991305A1 (ru) * | 2016-11-30 | 2019-10-31 | Производные тирозина и композиции, включающие их | |
| JP2020520923A (ja) | 2017-05-17 | 2020-07-16 | ボストン バイオメディカル， インコーポレイテッド | がんを処置するための方法 |
| KR102861344B1 (ko) * | 2020-09-28 | 2025-09-17 | 미츠비시 파워 가부시키가이샤 | 증기 터빈 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5599903A (en) * | 1992-04-03 | 1997-02-04 | Terrapin Technologies, Inc. | Glutathione analogs and paralog panels comprising glutathione mimics |
| US5556942A (en) * | 1991-04-29 | 1996-09-17 | Terrapin Technologies, Inc. | Glutathione S-transferase-activated compounds |
| US5545621A (en) * | 1991-04-29 | 1996-08-13 | Terrapin Technologies, Inc. | Glutathione S-transferase-activated compounds |
| US5955432A (en) * | 1992-04-03 | 1999-09-21 | Terrapin Technologies, Inc. | Metabolic effects of certain glutathione analogs |
| US5767147A (en) * | 1995-04-21 | 1998-06-16 | The Regents Of The University Of California | Inhibition of glutathione transferase by haloenol lactones |
| ATE280582T1 (de) * | 1995-06-07 | 2004-11-15 | Telik Inc | Stoffwechseleffekt von bestimmten glutation analogen |
| US5880097A (en) * | 1996-01-04 | 1999-03-09 | Terrapin Techologies, Inc. | Tethered prodrugs |
| US20030073837A1 (en) * | 1998-12-31 | 2003-04-17 | Langecker Peter J. | 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy |
| US6281223B1 (en) * | 1999-04-13 | 2001-08-28 | Supergen, Inc. | Radioenhanced camptothecin derivative cancer treatments |
| GB9909925D0 (en) * | 1999-04-29 | 1999-06-30 | Pharmacia & Upjohn Spa | Combined preparations comprising anthracycline derivatives |
| WO2001060365A1 (en) * | 2000-02-17 | 2001-08-23 | Merck & Co., Inc. | Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug |
| JP2004523517A (ja) * | 2000-12-22 | 2004-08-05 | ブリストル−マイヤーズ スクイブ カンパニー | 腫瘍増殖および転移を調節するための方法 |
| TW200538149A (en) * | 2004-05-20 | 2005-12-01 | Telik Inc | Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound |
-
2003
- 2003-11-13 TW TW092131777A patent/TWI323662B/zh not_active IP Right Cessation
- 2003-11-14 AR ARP030104215A patent/AR042051A1/es not_active Application Discontinuation
- 2003-11-14 KR KR1020057008697A patent/KR20050075018A/ko not_active Ceased
- 2003-11-14 AU AU2003290805A patent/AU2003290805A1/en not_active Abandoned
- 2003-11-14 JP JP2004553614A patent/JP2006508980A/ja active Pending
- 2003-11-14 US US10/714,593 patent/US20040138140A1/en not_active Abandoned
- 2003-11-14 BR BR0316364-4A patent/BR0316364A/pt not_active IP Right Cessation
- 2003-11-14 WO PCT/US2003/036209 patent/WO2004045593A2/en not_active Ceased
- 2003-11-14 MX MXPA05005200A patent/MXPA05005200A/es active IP Right Grant
- 2003-11-14 EP EP03783388A patent/EP1562564A2/en not_active Withdrawn
- 2003-11-14 CN CN2009101430576A patent/CN101590229B/zh not_active Expired - Fee Related
- 2003-11-14 CA CA002505377A patent/CA2505377A1/en not_active Abandoned
- 2003-11-14 CN CNB2003801034043A patent/CN100508961C/zh not_active Expired - Fee Related
-
2007
- 2007-10-15 US US11/872,659 patent/US20080159980A1/en not_active Abandoned
-
2010
- 2010-02-10 AU AU2010200483A patent/AU2010200483A1/en not_active Abandoned
- 2010-07-16 JP JP2010162154A patent/JP2010265305A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW200412933A (en) | 2004-08-01 |
| CN101590229B (zh) | 2012-12-05 |
| AU2010200483A1 (en) | 2010-03-04 |
| CN101590229A (zh) | 2009-12-02 |
| AR042051A1 (es) | 2005-06-08 |
| CN100508961C (zh) | 2009-07-08 |
| CA2505377A1 (en) | 2004-06-03 |
| JP2006508980A (ja) | 2006-03-16 |
| US20040138140A1 (en) | 2004-07-15 |
| MXPA05005200A (es) | 2005-08-18 |
| TWI323662B (en) | 2010-04-21 |
| AU2003290805A1 (en) | 2004-06-15 |
| KR20050075018A (ko) | 2005-07-19 |
| EP1562564A2 (en) | 2005-08-17 |
| WO2004045593A3 (en) | 2004-08-12 |
| CN1711076A (zh) | 2005-12-21 |
| WO2004045593A2 (en) | 2004-06-03 |
| US20080159980A1 (en) | 2008-07-03 |
| JP2010265305A (ja) | 2010-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0316364A (pt) | Combinação de terapia do câncer com um composto anticâncer ativado com gst e uma outra terapia anticâncer | |
| BRPI0511296A (pt) | sensibilização à outra terapia anticáncer e/ou melhora de um efeito colateral de outra terapia anticáncer por tratamento com um composto anticáncer ativado por gst | |
| BR0316050A (pt) | Métodos de tratar, controlar ou prevenir um câncer especìfico e doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com terapia de radiação, terapia hormonal, terapia biológica, ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit | |
| BRPI0411451A (pt) | formas de dosagens orais de memantina | |
| BR0009647A (pt) | Docetaxel em combinação com rhumab her2 para o tratamento de cânceres | |
| RU2010133489A (ru) | Применение ингибиторов гамма-секретазы для лечения рака | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| BRPI0507966A (pt) | uso de meloxicam para o tratamento de doenças respiratórias em porcos | |
| BRPI0407897A (pt) | derivados de cianopiridina úteis no tratamento de cáncer e outros distúrbios | |
| BRPI0411024A (pt) | métodos para induzir a eritropoiese intensificada ou completa em um paciente, para tratar ou prevenir doenças, e para aumentar a produção da eritropoietina na presença de uma citocina em um paciente, uso de um composto, kit, e, composição farmacêutica | |
| BRPI0410306A (pt) | métodos para tratar, controlar ou evitar um cáncer especìfico, para tratar, controlar ou evitar uma doença associada com angiogênese indesejada e para reduzir ou evitar um efeito adverso, composição farmacêutica, e, kit | |
| CA2531862A1 (en) | Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability | |
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| BRPI0406883A (pt) | Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto | |
| BRPI0518266A2 (pt) | medicamento oral de libertaÇço modificada de pelo menos um princÍpio ativo sob a forma multimicrocapsular | |
| BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
| BRPI0409427A (pt) | composto, uso do mesmo, composição farmacêutica, método de tratamento de um humano sofrendo de uma doença hiperproliferativa, e, processo para a preparação de um composto ou de um sal, éster ou pró-droga farmaceuticamente aceitáveis do mesmo | |
| TNSN07419A1 (en) | Methods for treating drug resistant cancer | |
| BRPI0412919A (pt) | combinação de antagonista de mglur2 e inibidor de ache para o tratamento de distúrbios neurológicos crÈnicos e/ou agudos | |
| ZA202210355B (en) | Compositions and therapeutic uses of cannabidiol | |
| BRPI0409796A (pt) | uso de dipiridamol ou mopidamol para tratamento e prevenção de doenças tromboembolìticas e distúrbios provocados pela formação excessiva de trombina e/ou pela expressão elevada de receptores de trombina | |
| PA8627601A1 (es) | Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-ilo]-(4-bromo-3-metil-5-propoxi-tiofen-2-ilo)-metanona hidrocloruro como un inhibidor de triptasa de mastocitos | |
| NO20044498L (no) | Kombinasjonsterapi for behandling av cancer | |
| AR065582A1 (es) | Mejoras en composiciones medicinales o relativas a las mismas | |
| BRPI0510895A (pt) | formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2280 DE 16/09/2014. |